The clinical relevance of tacrolimus trough levels in outpatients with active ulcerative colitis

Makoto Naganuma, Yasuo Suzuki, Katsuyoshi Matsuoka, Reiko Kunisaki, Naoki Yoshimura, Masakazu Nagahori, Mamoru Watanabe

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We investigated the safety, clinical efficacy, and significance of tacrolimus trough levels in 20 outpatients with active ulcerative colitis. Adverse effects were observed in 16 (80%) patients, and most events were reversible and showed improvement or complete recovery. Three patients required hospitalization because of disease aggravation. The rate of efficacious tacrolimus trough levels was 60% within 1 week and 95% within 2 weeks. At 12 weeks, the clinical remission rate was 25% and the improvement rate was 55%. The clinical remission rate was significantly higher in patients with the relapse-remission type than in those with the chronic inflammation type. These results indicate that the use of tacrolimus in outpatients with ulcerative colitis is safe and that efficacious trough levels can be rapidly achieved in these patients.

Original languageEnglish
Pages (from-to)276-287
Number of pages12
JournalJournal of Japanese Society of Gastroenterology
Volume111
Issue number2
Publication statusPublished - 2014 Feb

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'The clinical relevance of tacrolimus trough levels in outpatients with active ulcerative colitis'. Together they form a unique fingerprint.

Cite this